currentstudies.htm

Department of Emergency Medicine

End of Study Press Release
Do You or a Family Member Have Seizures?

RAMPART

University of Kentucky Department of Emergency Medicine has completed its participation in a clinical research study called RAMPART, the Rapid Anticonvulsant Medications Prior to Arrival Trial. This nation-wide study has reached its enrollment target and has stopped enrolling patients across the country. RAMPART was an EMS trial designed to study if seizure drug given as a shot in the muscle was just as effective as seizure drug given through an IV into the vein at stopping seizures.

Residents within the communities served by the Lexington Fire/EMS who opted-out of the trial by wearing a “RAMPART Declined” bracelet can now stop wearing this bracelet.

Results from this study will be released to the local public and will also be available on the RAMPART website at rampart.umich.edu after the data has been analyzed.

For more information, contact Linda Dechtenberg, RAMPART Study, Clinical Research Nurse at 859-257-6703.

PROTECT III Study:

Dr. Humphries is an Emergency Medicine Physician and the Principal Investigator for the PROTECT III research study.

The University of Kentucky’s Department of Emergency Medicine is participating in a research study entitled, Progesterone for Traumatic Brain Injury (TBI): an Experimental Clinical Trial. Better known as ProTECT III, the study is part of the National Institutes of Health’s exploration into treatments for brain injuries.

Specifically, ProTECT III, will study treatment options for moderate to severe TBI, and UK wil serve as one of 17 hubs across the country for this landmark study.

Protect III will use progesterone, a hormone normally found in the
human body, to see if it reduces the damage caused by traumatic brain injuries. Progesterone won’t reverse the damage to the brain caused by the initial injury, but researchers hope it will lessen the harmful effects caused by the ruptured blood vessels, bruising and swelling on brain tissures. Currently there is no specific drug treatment for TBI.

Normally, researchers get permission (consent) before a person can be included in a research study. A person with a traumatic brain injury will not be able to give consent at the time of injury. Since TBI must be treated quickly, there might not be enough time to locate and talk to the person’s next of kin about the study, so it’s possible that a person might be enrolled in the study without the consent of his or her next of kin. This is called "Exception from Informed Consent" (EFIC). Once the legal guardian is located, they will be asked to give permission for you to continue in the study.

The purpose of this poster is to notify our community about this research study and to provide contact information and resources where you can learn more, including an option to decline participation.

Local ProTECT III Contact Information
University of Kentucky College of Medicine,
Department of Emergency Medicine
Phone: 859-323-1771
E-mail: joann.short@uky.edu
Website: www.ukprotectbrain.com